ESTG - a friend passed this email from a couple of days ago on to me, actually two of them, but they read the same.
---------------------
From: BULL STOCKS <bullstocks@xmail.com>
To: news@bull-stocks.biglist.com <news@bull-stocks.biglist.com>
Date: Wednesday, July 26, 2000 6:57 AM
Subject: [news] ESTG
>ELAST TECHNOLOGIES (OTC BB: ESTG)
>
>
>BULL STOCKS
>
>
>ELAST TECHNOLOGIES (OTC BB: ESTG) has just released the following news. The
significance of this breakthrough is massive - allergy testing is estimated
to be a $6 billion annual market in the U.S. and a $12 billion annual market
worldwide.
>
>Even before the release of this news, analysts were bullish on ESTG. Donner
Corp., an investment-banking firm and member of NASD and SIPC, has issued a
thorough research report analyzing the investment opportunity offered by
ELAST TECHNOLOGIES and concluding that, as ESTG has the potential for
substantial growth, its stock is ``highly undervalued''.
>
>
>ELAST TECHNOLOGIES, INC. ANNOUNCES SIGNIFICANT INNOVATION IN THE
DEVELOPMENT OF ITS ALLERGY TESTING DEVICE
>
>LAS VEGAS--July 26, 2000--ELAST Technologies, Inc., (OTC-BB: ESTG)
elast.com announced this morning that it has successfully
enhanced the diagnostic capabilities of its allergy-testing device (the
ELAST Device(TM)) through the development of an additional non-invasive
method of exposing the testing subject to a potential allergen.
>
>The ELAST Device(TM) is a patented, non-invasive diagnostic tool designed
to accurately diagnose allergies, as well as food and chemical sensitivities
immediately and without any of the pain or expense associated with currently
employed testing methods. Current allergy testing methods include the oral
challenge test as well as blood and skin prick testing. These methods all
include the introduction of the potential allergen to the body with
concomitant discomfort and risks. In contrast, the ELAST Device(TM) is being
designed to test for allergies and sensitivities non-invasively through
means of simple exposure, without the introduction into the body of the
potential allergen.
>
>The ELAST Device(TM) is based upon the clinical observation that the normal
flow of electricity in the human body is altered when its immune system is
exposed to a substance to which it is sensitive or allergic. The
non-invasive nature of the ELAST Device(TM) is possible because the device
measures the body's electrical response when it is exposed to an allergen,
and through this measurement the ELAST Device(TM) assesses the testing
subject's profile of reactions to various substances. "By employing the
breakthrough announced today ELAST's scientists now have an alternative
non-invasive method of exposing the testing subject to a potential allergen,
thereby increasing the opportunities to measure the alteration in the body's
electrical response to a sensitivity," stated ELAST Technologies' founder
and Chief Scientist Robert D. Milne, M.D.
>
>ELAST Technologies is a research and development enterprise whose primary
business is the development of the Electronic Allergo Sensitivity Test
(ELAST Device(TM)). The U.S. allergy testing market is estimated to be a $6
billion annual market (and is estimated to be a $12 billion annual market
worldwide).
>
>Additional information about the Company can be found at
elast.com and xcelassociates.com .
>
>This news release contains forward-looking statements. Forward-looking
statements include statements concerning plans, objectives, goals,
strategies, future events or performance and underlying assumptions and
other statements that are other than statements of historical facts. These
statements are subject to uncertainties and risks including, but not limited
to, product development and consumer demand and acceptance, changes in
technology, ability to raise capital, the availability of appropriate
acquisition candidates and/or business partnerships, economic conditions,
impact of competition and pricing, capacity and supply constraints or
difficulties, government regulation and other risks. All such
forward-looking statements whether written or oral, and whether made by or
on behalf of the Company are expressly qualified by these cautionary
statements and any other cautionary statements which may accompany the
forward-looking statements. In addition, the Company disclaims any !
>obligation to update any forward-looking statements to reflect events or
circumstances after the date hereof.
>
>
>IMPORTANT DISCLAIMER AND DISCLOSURE: Verify all claims and do your own due
diligence. This is not a solicitation or recommendation to buy, sell or hold
securities. Bull Stocks is not offering securities for sale. An offer to buy
or sell can be made only with accompanying disclosure documents and only in
the states and provinces for which they are approved. All statements and
expressions are the sole opinion of the editors and are subject to change
without notice. Bull Stocks is not liable for any investment decisions by
its readers or subscribers. It is strongly recommended that any purchase or
sale decision be discussed with a financial adviser or broker prior to
completing any such purchase or sale decision. Bull Stocks is not a
registered investment adviser, or a broker-dealer, or a member of any
financial regulatory bodies. The information contained herein is provided as
an information service only. The accuracy or completeness of the information
is not warranted and is on!
>ly as reliable as the sources from which it was obtained. It should be
understood that there is no guarantee past performance will be indicative of
future results. Investors are cautioned that they may lose all or a portion
of their investment if they make a purchase in Bull Stocks featured stocks.
In order to be in full compliance with the Securities Act of 1933, Section
17(b), management of Bull Stocks is receiving 25,000 shares of Elast
Technologies Inc. from Xcel Associates Inc. Since management of Bull Stocks
is receiving compensation and holds stock in the featured company there is
an inherent conflict of interest in Bull Stocks statements and opinions and
such statements and opinions cannot be considered independent. Management of
Bull Stocks will benefit from any increase in share price of the featured
company. Information within Bull Stocks contains “forward looking”
statements within the meaning of Section 27A of the Securities Act of 1933
and Section 21E of the Secu!
>rities Exchange Act of 1934. Any statements that express or involve
discussions with respect to predictions, expectations, beliefs, plans,
projections, objectives, goals, assumptions or future events or performance
are not statements of historical facts and may be forward looking
statements. Forward looking statements are based on expectations, estimates
and projections at the time the statements are made that involve a number of
risks and uncertainties which could cause actual results or events to differ
materially from those presently anticipated. Forward looking statements may
be identified through the use of words such as expects, will, anticipates,
estimates, believes, or by statements indicating certain actions may, could
or might occur. Bull Stocks encourages its readers to invest carefully and
read the investor information available at the Web sites of the Securities
and Exchange Commission (SEC) at sec.gov and/or the National
Association of Securities Deale!
>rs (NASD) at nasd.com. Readers can review all public filings by
companies at the SEC s EDGAR page. The NASD has published information on how
to invest carefully at its Web site.
> |
